Medicines Under Close Monitoring
List of medicines under close safety monitoring
The list includes SFDA authorized medicines in the following categories:
• New active substances.
• New biological products and biosimilars.
• Advanced therapy medicinal products
• Breakthrough medicines.
• Medicines associated with genomic variations.
• Medicines with potential class-effect safety concerns.
• Medicines requiring further safety monitoring in special populations.
List of medicinal products under close monitoring (XLSX)
Proactive Drug Safety Monitoring Program
In 2019, the Saudi Food and Drug Authority (SFDA) launched the Proactive Drug Safety Monitoring Program to proactively monitor the post-marketing safety of all registered medicinal products in Saudi Arabia. The program aims to enhance the effectiveness and efficiency of post-marketing safety surveillance.
Program Objectives
The objectives of the program are to:
• Develop an efficient and sustainable framework for monitoring the safety of marketed medicinal products in Saudi Arabia.
• Establish a proactive approach to detecting potential safety signals.
• Conduct formal assessments of identified safety concerns and share the findings with relevant stakeholders and the scientific community.
• Enhance medication safety in the Kingdom.
SFDA Action Plan and Safety Assessment Approach
The SFDA's action plan involves conducting comprehensive drug safety assessments using multiple sources of evidence, including:
• Causality assessment of global Individual Case Safety Reports (ICSRs) retrieved from the World Health Organization (WHO) global database, VigiBase.
• Local adverse drug reaction reports retrieved from the SFDA's National Pharmacovigilance Center database.
• Published scientific literature.
• Safety reviews and assessments conducted by stringent regulatory authorities.
• Periodic Benefit-Risk Evaluation Reports (PBRERs).
The WHO-Uppsala Monitoring Centre (UMC) causality assessment system and the Bradford Hill criteria are used to evaluate the potential association between targeted medicinal products and identified safety signals.
Based on the findings of the safety assessment, appropriate regulatory actions may be recommended.
Potential Regulatory Actions
The outcome of the benefit-risk assessment may lead to one or more of the following regulatory actions:
• Updating the product information
• Modifying the product's marketing authorization status, including restricting approved indications or specific patient populations, suspending or withdrawing the marketing authorization.
• Implementing additional risk minimization measures.
• Requesting additional safety data from pharmaceutical companies.
• Maintaining the identified safety signal under routine monitoring.
In certain cases, the assessment may conclude that no additional regulatory action is necessary.
Ongoing Projects Under This Initiative
• Safety Monitoring of Newly Registered Medicinal Products, Including New Chemical Entities (NCEs) and Biological Products
• Pharmacogenomics–Pharmacovigilance Project
• Drug Class Effect Safety Monitoring
• Advanced Therapy Medicinal Products (ATMPs) Safety Monitoring
• Breakthrough Medicines Safety Monitoring
• Orphan Drugs Safety Monitoring
• Follow-up of Safety Signals Under Monitoring
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.